Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy
Ayman R. Fath, Amro Aglan, Martin S. Maron, Jason S. Phillips, Barry J. Maron, Ethan J Rowin
Topics & Concepts
MedicineHypertrophic cardiomyopathyInternal medicineAgonistCardiologyCardiomyopathyGlucagon-like peptide-1EndocrinologyGlucagonDiabetes mellitusInsulinHeart failureReceptorType 2 diabetesDiabetes Treatment and ManagementHeart Failure Treatment and ManagementCardiovascular Function and Risk Factors